<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Radiat Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Radiat Oncol</journal-id><journal-title-group><journal-title>Radiation Oncology (London, England)</journal-title></journal-title-group><issn pub-type="epub">1748-717X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26014350</article-id><article-id pub-id-type="pmc">4490759</article-id><article-id pub-id-type="publisher-id">422</article-id><article-id pub-id-type="doi">10.1186/s13014-015-0422-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Regional recurrence of oropharyngeal cancer after definitive radiotherapy: a case control study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>S&#x000f6;derstr&#x000f6;m</surname><given-names>Karin</given-names></name><address><email>karin.soderstrom@onkologi.umu.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Nilsson</surname><given-names>Per</given-names></name><address><email>per.nilsson@skane.se</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Dalianis</surname><given-names>Tina</given-names></name><address><email>tina.dalianis@ki.se</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Kjell&#x000e9;n</surname><given-names>Elisabeth</given-names></name><address><email>elisabeth.kjellen@med.lu.se</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Zackrisson</surname><given-names>Bj&#x000f6;rn</given-names></name><address><email>bjorn.zackrisson@umu.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Department of Radiation Sciences, Oncology, Ume&#x000e5; University Hospital, Ume&#x000e5; University, Ume&#x000e5;, Sweden </aff><aff id="Aff2"><label/>Department of Oncology and Radiation Physics, Sk&#x000e5;ne University Hospital, Lund University, Lund, Sweden </aff><aff id="Aff3"><label/>Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>5</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>5</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><elocation-id>117</elocation-id><history><date date-type="received"><day>21</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; S&#x000f6;derstr&#x000f6;m et al. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Elective treatment of lymph nodes in oropharyngeal cancer (OPC) has impact on both regional recurrences (RR) and risk of late side effects. This study was performed to quantify the dose-dependent impact on RR and overall survival (OS) in a prospectively collected cohort of OPC from the ARTSCAN study with emphasis on elective treatment.</p></sec><sec><title>Methods</title><p>ARTSCAN is a previously published prospective, randomized, multicentre study of altered radiotherapy (RT) fractionation in head and neck cancer. In ARTSCAN the elective treatment volume for node positive OPC varied significantly between centres due to local treatment principles. All patients with OPC in complete response after primary treatment were eligible for the present case&#x02013;control study. Cases were patients with RR during five years follow-up. Patients with no recurrence were eligible as controls. Four controls per case were matched according to T- and N-stage. Mean (<italic>D</italic><sub>mean</sub>) and median (<italic>D</italic><sub>50%</sub>) dose for the lymph node level (LNL) of RR in the cases and the corresponding LNL in the controls were analysed with conditional logistic regression. OS was estimated with the Kaplan-Meier method and evaluated by multivariate Cox regression analysis.</p></sec><sec><title>Results</title><p>There was a dose-dependent risk reduction for <italic>D</italic><sub>50%</sub> in the interval that represented elective treatment (40&#x02013;50&#x000a0;Gy) (OR&#x02009;=&#x02009;0.18, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) and a trend in the same dose interval for <italic>D</italic><sub>mean</sub> (OR&#x02009;=&#x02009;0.19, <italic>p</italic>&#x02009;=&#x02009;0.07). OS rates at five years were 0.39 (0.24-0.65) for cases and 0.70 (0.62&#x02013;0.81) for controls (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). The Kaplan-Meier and the Cox regression analysis for cases categorised by delivered dose showed an inverse relationship between dose and survival. The cases with RR in a LNL outside planning target volume (PTV) (<italic>D</italic><sub>mean</sub>&#x02009;&#x0003c;&#x02009;40&#x000a0;Gy) had an OS rate comparable to that of all patients, and those with RR in a LNL in PTV<sub>elective</sub> (<italic>D</italic><sub>mean</sub> 40&#x02013;60&#x000a0;Gy) or PTV<sub>tumour</sub> (<italic>D</italic><sub>mean</sub> &#x0003e;60&#x000a0;Gy) did significantly worse (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). The same inverse relationship was also shown for a small subset of patient with known HPV-status, defined by over expression of p16 (<italic>p&#x02009;&#x0003c;</italic>&#x02009;0.05).</p></sec><sec><title>Conclusions</title><p>There was a significant risk reduction for RR of elective treatment. However the OS for patients with RR outside target volumes was not affected, with similar results for patients with HPV-positive OPC. This could be an argument for a prospective randomized study on limited elective target volumes in OPC.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Elective radiotherapy (RT) of clinically negative regional lymph nodes has been part of the standard treatment in head and neck squamous cell carcinoma (HNSCC) for many decades [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Several retrospective studies have shown the efficacy of this treatment, but few studies have addressed the dose&#x02013;response relationships based on the actual dose distribution to the lymph nodes rather than prescribed dose [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. On the other hand, knowledge about relationships between side effects and doses to organs at risk (OARs) is expanding. A number of models that estimate the probability of normal tissue complications link different dose-volume descriptors for OARs with the incidence of specific side effects, for example dysphagia [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>Since the introduction of three dimensional conformal radiotherapy (3D-CRT) and later intensity modulated radiotherapy (IMRT) and volumetric arc therapy with highly conformal dose distributions, it is possible to better spare OARs to reduce side effects [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. One specific sub-group of HNSCC, oropharyngeal cancer (OPC), has undergone a transformation during the last decades. The disease occurs at a younger age and is more often associated with human papilloma virus (HPV) than with tobacco and alcohol abuse [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>As the treatment options evolve and the disease itself changes a reassessment of the current treatment seems motivated.</p><p>ARTSCAN was a prospective randomised controlled multi-centre study on accelerated versus conventional fractionation [<xref ref-type="bibr" rid="CR20">20</xref>]. No significant differences between the fractionation schedules concerning tumour control or late side effects were detected. A large proportion of the patients (48&#x000a0;%) had OPC. At the time of the study there was no clear national consensus on elective treatment. In the study protocol, the elective target volume was specified as &#x0201c;the standard recommendation at each treating institution&#x0201d; with a dose prescription of 46&#x000a0;Gy in 23 fractions, 5&#x000a0;days per week, in both treatment arms. Some centres practiced limited elective treatment with unilateral and selective (not treating all LNL of the neck) treatment and some used bilateral treatment including all LNL of the neck in node positive disease. There was a significant difference, up to a factor of two, between different study sites regarding the volumes prescribed for elective treatment in node positive OPC [<xref ref-type="bibr" rid="CR21">21</xref>]. Due to this variation in elective treatment volume, not solely dependent on tumour stage, it is reasonable to use this prospectively collected material to estimate a dose&#x02013;response relationship for regional recurrences corrected for T- and N -stage.</p><p>Therefore we studied the dose-dependent risk reduction of neck node recurrences as well as survival based on regional recurrences in patients treated with definitive RT in this prospectively collected cohort of OPC.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Objectives and study design</title><p>The objectives of the study were:<list list-type="order"><list-item><p>To compare mean and median dose of a lymph node level (LNL) with a regional recurrence to mean and median dose of the corresponding LNL in matched controls without recurrence. This was carried out as a case&#x02013;control study.</p></list-item><list-item><p>To analyse the impact of regional recurrence on overall survival (OS). This was done both for cases vs. controls and for cases grouped according to mean dose separately.</p></list-item></list></p></sec><sec id="Sec4"><title>Patients</title><p>The cohort from which the cases and controls were recruited consisted of all OPC patients with complete response to primary treatment in an earlier reported prospective randomised controlled trial, ARTSCAN [<xref ref-type="bibr" rid="CR20">20</xref>]. Complete response, in this study, was defined as no residual tumour after primary treatment and no local or regional failure within 6&#x000a0;months after randomisation. The ARTSCAN study was approved by the participating centres&#x02019; local Ethics Committees (Regional ethics committee Ume&#x000e5;) and 733 eligible patients with localised HNSCC signed informed consent between 1998 and 2006. About half of them (n&#x02009;=&#x02009;357) had OPC. Neither chemotherapy nor surgery, other than diagnostic, prior to RT was allowed. Neck dissection as part of primary treatment post RT was allowed according to clinical practice at each participating centre. The use of neck dissection post RT varied between centres where some practiced planned elective neck dissection and some centres used salvage neck dissection in patients with suspected/verified residual neck disease. For additional information on the original study, see [<xref ref-type="bibr" rid="CR20">20</xref>]. Two of the sites (Stockholm and Ume&#x000e5;) have since the publication of [<xref ref-type="bibr" rid="CR20">20</xref>] provided information on HPV-status (based on p16-expression as a surrogate marker) for patients with OPC. An extensive quality assurance process for the original study was performed and published [<xref ref-type="bibr" rid="CR21">21</xref>] with no major trends in the patient characteristics or treatment of OPC during the study period.</p><p>Cases for the present study were patients with a regional relapse with or without composite local relapse during follow up. They were identified by the clinical report form and verified in the patient chart. The remaining patients in the cohort with loco-regional control during the follow-up period of five years were eligible as controls. Frequency matching was performed based on T- and N-stage, and to optimise the statistical power of the study, four controls were chosen for each case.</p></sec><sec id="Sec5"><title>Radiotherapy</title><p>All patients received computed tomography (CT) based 3D-CRT (92&#x000a0;%) or IMRT (8&#x000a0;%) with dose prescriptions according to ICRU [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. The RT and the quality assurance of the trial have been described in detail elsewhere [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Patients included in the ARTSCAN trial were randomised between two fractionation schedules for the planning target volume encompassing macroscopic tumour (PTV<sub>tumour</sub>). The conventional fractionation schedule (CFx) consisted of 2&#x000a0;Gy fractions daily/5&#x000a0;days a week to a total dose of 68&#x000a0;Gy with a total treatment time &#x0003c;7&#x000a0;weeks. Patients receiving accelerated fractionation (AFx) were prescribed 2&#x000a0;Gy fractions daily/5&#x000a0;days a week plus a daily concomitant boost of 1.1&#x000a0;Gy to a total dose of 68&#x000a0;Gy with a total treatment time &#x0003c;5&#x000a0;weeks for PTV<sub>tumour</sub>. As stated in the introduction, all patients had a dose prescription of 46&#x000a0;Gy in 2&#x000a0;Gy fractions daily/5&#x000a0;days a week to the elective PTV (PTV<sub>elective</sub>), the extent of which was not stipulated in the protocol. The major difference between centres in respect to PTV<sub>elective</sub> was the use of unilateral selective treatment in T1-2 and N1-2b OPC.</p></sec><sec id="Sec6"><title>Data collection and localisation of regional relapse</title><p>The patients were clinically examined 4&#x02013;8 weeks after completion of RT to assess treatment result. During the first two years patients were monitored for loco-regional relapse and distant metastases every 3&#x000a0;months, and they were monitored every 6&#x000a0;months thereafter until five years after end of RT. OS was followed through the Swedish population registry.</p><p>Treatment plans (CT-images, structures, plans and dose distribution) from ARTSCAN were collected after RT was completed and stored in DICOM-RT format for additional analysis such as the present.</p><p>All cases had their charts revised including available radiological imaging to identify the LNL [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] of the regional relapse including side in respect to the primary tumour (ipsilateral vs. contralateral). The corresponding LNL for the controls including laterality was identified. A systematic delineation of the LNL according to [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>] was performed by one of the authors (KS) on the original CT-images for all cases and controls. Dose-volume data for these structures were derived from the original DICOM-RT dose files using the software package <italic>RT Bench</italic>&#x02122; (Cureos AB, Uppsala, Sweden).</p></sec><sec id="Sec7"><title>Dose-volume analysis</title><p>We analysed mean dose (<italic>D</italic><sub>mean</sub>) and median dose (<italic>D</italic><sub>50%</sub>) for the LNL of relapse in the cases and the corresponding LNL in the controls.</p><p>The derived doses for both cases and controls were grouped according to delivered dose to the LNL of interest for the calculation of any dose&#x02013;response relationships. Four dose intervals were chosen representing LNLs: outside PTV (0&#x02013;40&#x000a0;Gy), within PTV<sub>elective</sub> (40&#x02013;50&#x000a0;Gy), in PTV<sub>elective</sub> close to PTV<sub>tumour</sub> (50&#x02013;60&#x000a0;Gy), and PTV<sub>tumour</sub> (&#x0003e;60&#x000a0;Gy), respectively.</p></sec><sec id="Sec8"><title>Immunohistochemistry of p16</title><p>Tumour biopsy sections (4&#x02013;5&#x000a0;&#x003bc;m) were de-paraffinised and rehydrated, with antigen retrieval in citrate buffer (pH&#x000a0;6) and unspecific binding sites blocked with 1.5&#x000a0;% horse serum in PBS. The sections were then stained with mAb p16<sup>INKA4a</sup> (clone: JC8, dilution 1:100, Santa Cruz Biotech, Santa Cruz, CA, USA) at +8&#x000a0;&#x000b0;C overnight, before incubation for 45&#x000a0;min. with biotinylated anti-mouse antibody (dilution 1:200, Vector Laboratories, Burlingame, CA, USA). Alternatively, the slides were stained with the CINtec&#x000ae; p16 Histology (805&#x02013;4713), Ventana Medical Systems Inc., Arizona, USA by following the same protocol with the exception of incubation with the antibody for 1&#x000a0;h at room temperature. For antigen detection, the avidin&#x02013;biotin&#x02013;peroxidase complex (ABC) kit (Vectastain, Vector Laboratories, Burlingame, CA, USA) was used. Slides developed in chromogen 3&#x02019;-diaminobenzydine (DAB) (Vector Laboratories, Burlingame, CA, USA) and counterstained with haematoxylin were then washed and dehydrated, and the cover mounted using VectaMount permanent mounting media (Vector Laboratories, Burlingame, CA, USA). P16 staining was regarded as positive if &#x0003e;70&#x000a0;% of the tumour cells were strongly p16-positive [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec9"><title>Statistical analysis</title><p>For univariate analyses the Pearson Chi-Squared-test and Fisher&#x02019;s exact test were used. The odds ratios for <italic>D</italic><sub>mean</sub> and <italic>D</italic><sub>50%</sub> grouped according to dose intervals were calculated using conditional logistic regression. Clinically suspected interactions with the dose&#x02013;response data were also evaluated in the model.</p><p>The Kaplan-Meier method was used to estimate OS for all patients calculated from start of RT to death or censoring. Univariate survival time comparisons between cases and controls as well as between cases divided by mean dose to LNL of interest were performed using the log-rank test. Kaplan-Meier survival curves were complemented with a multivariate Cox regression, adjusting for potential confounders. All two-way interaction terms were evaluated in the model.</p><p>All tests were two-sided and <italic>p</italic>-value of less than 0.05 was considered statistically significant.</p><p>Data were analysed with the statistical software package R (version 2.15.2; R Development Core Team, R foundation for Statistical Computing, Vienna, Austria).</p></sec></sec><sec id="Sec10" sec-type="results"><title>Results</title><sec id="Sec11"><title>Eligibility and patient characteristics</title><p>In the cohort of OPC patients with complete response from ARTSCAN, 23 cases with a recurrence in the lymph nodes of the neck were identified corresponding to a regional relapse rate of 7.2&#x000a0;%. Five (22&#x000a0;%) of these regional recurrences had a composite local recurrence. A majority of the cases (95.6&#x000a0;%) and the controls (96.6&#x000a0;%) were in clinical stage III-IV (UICC, Geneva, 1987). 46.6&#x000a0;% of the controls and 43.5&#x000a0;% of the cases were treated with the AFx-schedule. Median age (58&#x000a0;years for cases and 59&#x000a0;years for controls) and other tumour and patient characteristics, including predictive factors reported in [<xref ref-type="bibr" rid="CR20">20</xref>], showed no significant difference between cases and controls (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). About half of the patients had a neck dissection as part of their primary treatment post RT, and for those the pathology specimen was reviewed for viable tumour (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In the subset (n&#x02009;=&#x02009;42) with reported HPV-status (based on p16 expression) there was no significant difference between cases and controls (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). In conclusion, none of the tested two-way interactions differed between cases and controls.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient and tumour characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2"/><th>Controls</th><th>Case</th><th>Total</th><th/></tr><tr><th>n (%)</th><th>n (%)</th><th>n (%)</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td rowspan="5">T</td><td>1</td><td>19 (21.6)</td><td>5 (21.7)</td><td>24 (21.6)</td><td rowspan="5">1.000</td></tr><tr><td>2</td><td>28 (31.8)</td><td>7 (30.4)</td><td>35 (31.5)</td></tr><tr><td>3</td><td>24 (27.3)</td><td>6 (26.1)</td><td>30 (27.0)</td></tr><tr><td>4</td><td>17 (19.3)</td><td>5 (21.7)</td><td>22 (19.8)</td></tr><tr><td>Total</td><td>89 (100)</td><td>23 (100)</td><td>111 (100)</td></tr><tr><td rowspan="6">N</td><td>0</td><td>10 (11.4)</td><td>3 (13.0)</td><td>13 (11.7)</td><td rowspan="6">0.069</td></tr><tr><td>1</td><td>23 (26.1)</td><td>2 (8.7)</td><td>25 (22.5)</td></tr><tr><td>2A</td><td>25 (28.4)</td><td>4 (17.4)</td><td>29 (26.1)</td></tr><tr><td>2B</td><td>15 (17.0)</td><td>10 (43.5)</td><td>25 (22.5)</td></tr><tr><td>2C/3</td><td>15 (17.0)</td><td>4 (17.4)</td><td>19 (17.1)</td></tr><tr><td>Total</td><td>89 (100)</td><td>23 (100)</td><td>111 (100)</td></tr><tr><td rowspan="3">Sex</td><td>male</td><td>66 (75.0)</td><td>19 (82.0)</td><td>85 (76.6)</td><td rowspan="3">0.584</td></tr><tr><td>female</td><td>22 (25.0)</td><td>4 (17.4)</td><td>26. (23.4)</td></tr><tr><td>Total</td><td>88 (100)</td><td>23 (100)</td><td>111 (100)</td></tr><tr><td rowspan="3">Hb conc</td><td>&#x0003c;140</td><td>37 (49.3)</td><td>14 (66.7)</td><td>51 (53.1)</td><td rowspan="3">0.217</td></tr><tr><td>&#x0003e;140</td><td>38 (50.7)</td><td>7 (33.3)</td><td>45 (46.9)</td></tr><tr><td>Total</td><td>75 (100)</td><td>21 (100)</td><td>96 (100)</td></tr><tr><td rowspan="3">PS <italic>Karnofsky</italic>
</td><td>&#x0003c;90</td><td>6 (7.2)</td><td>3 (13)</td><td>9 (8.5)</td><td rowspan="3">0.465</td></tr><tr><td>&#x0003e;90</td><td>77 (92,8)</td><td>20 (87)</td><td>97 (91.5)</td></tr><tr><td>Total</td><td>83 (100)</td><td>23 (100)</td><td>106 (100)</td></tr><tr><td rowspan="3">HPV-status (&#x0003e;70&#x000a0;% p16+)</td><td>+</td><td>28 (82.4)</td><td>6 (75.0)</td><td>34 (81.0)</td><td rowspan="3">0.635</td></tr><tr><td>-</td><td>6 (17.6)</td><td>2 (25.0)</td><td>8 (19.0)</td></tr><tr><td>Total</td><td>34 (100)</td><td>8 (100)</td><td>42 (100)</td></tr></tbody></table></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Neck dissection (ND) as part of primary treatment after definitive RT</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2"/><th>Control</th><th>Case</th><th>Total</th><th>
<italic>p</italic> value</th></tr><tr><th>n (%)</th><th>n (%)</th><th>n (%)</th><th/></tr></thead><tbody><tr><td rowspan="3">ND</td><td>Yes</td><td>54 (61.4)</td><td>11 (47.8)</td><td>65 (58.6)</td><td rowspan="3">0.342</td></tr><tr><td>No</td><td>34 (38.6)</td><td>12 (52.2)</td><td>46 (41.4)</td></tr><tr><td>Total</td><td>88 (100)</td><td>23 (100)</td><td>111 (100)</td></tr><tr><td rowspan="3">If ND, viable tumour present</td><td>Yes</td><td>15 (27.8)</td><td>3 (27.3)</td><td>18 (28.1)</td><td rowspan="3">0.219</td></tr><tr><td>No</td><td>39 (72.2)</td><td>7 (63.6)</td><td>46 (71.2)</td></tr><tr><td>Total</td><td>54 (100)</td><td>10 (100)</td><td>64 (100)</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec12"><title>Dose&#x02013;response relationships</title><p>The dose&#x02013;response relationships, presented as odds ratios, between cases and controls for the analysed dose intervals including the number of cases and controls analyzed in each interval are presented in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. There was a significant risk reduction for a RR in <italic>D</italic><sub>50%</sub> for the interval representing elective treatment (40&#x02013;50&#x000a0;Gy) and a trend for <italic>D</italic><sub>mean</sub> in the same dose interval. We have evaluated the model by adjusting for treatment type and neck dissection without any alterations in the significance levels presented in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Dose&#x02013;response relationship</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Dose interval</th><th rowspan="2">OR</th><th rowspan="2">
<italic>p</italic> value</th></tr><tr><th>No of RR/controls</th></tr></thead><tbody><tr><td colspan="3">Mean dose, <italic>D</italic>
<sub>mean</sub>
</td></tr><tr><td>10&#x02013;40</td><td rowspan="2">0.85</td><td rowspan="2">0.856</td></tr><tr><td>
<italic>5/9</italic>
</td></tr><tr><td>40&#x02013;50</td><td rowspan="2">0.19</td><td rowspan="2">0.073</td></tr><tr><td>
<italic>3/27</italic>
</td></tr><tr><td>50&#x02013;60</td><td rowspan="2">0.33</td><td rowspan="2">0.326</td></tr><tr><td>
<italic>2/9</italic>
</td></tr><tr><td>&#x0003e;60</td><td rowspan="2">0.48</td><td rowspan="2">0.453</td></tr><tr><td>
<italic>9/29</italic>
</td></tr><tr><td>
<italic>Reference&#x02009;=&#x02009;dose category 0&#x02013;10</italic>
</td><td rowspan="2"/><td rowspan="2"/></tr><tr><td>
<italic>4/6</italic>
</td></tr><tr><td colspan="3">Median dose, <italic>D</italic>
<sub>50%</sub>
</td></tr><tr><td>10&#x02013;40</td><td rowspan="2">0.93</td><td rowspan="2">0.935</td></tr><tr><td>
<italic>4/7</italic>
</td></tr><tr><td>40&#x02013;50</td><td rowspan="2">0.18</td><td rowspan="2">0.049</td></tr><tr><td>
<italic>3/34</italic>
</td></tr><tr><td>50&#x02013;60</td><td rowspan="2">1.57</td><td rowspan="2">0.705</td></tr><tr><td>
<italic>2/2</italic>
</td></tr><tr><td>&#x0003e;60 <italic>9/31</italic>
</td><td>0.65</td><td>0.650</td></tr><tr><td colspan="3">Reference&#x02009;=&#x02009;dose category 0&#x02013;10</td></tr><tr><td colspan="3">
<italic>4/6</italic>
</td></tr></tbody></table><table-wrap-foot><p>Relationship between dose to lymph node level (LNL) of interest and regional recurrences presented as odds ratio (OR). Dose interval presented in Gy, the distribution of cases/controls per dose interval is presented below the dose interval</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Survival</title><p>OS rates (95&#x000a0;% CI) at five and twelve years for the cohort were 0.72 (0.68&#x02013;0.77) and 0.57 (0.5&#x02013;0.65). A RR resulted in significantly reduced OS (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The OS rates at five and twelve years were 0.39 (0.24&#x02013;0.65) and 0.29 (0.15&#x02013;0.56) for the cases and 0.7 (0.62&#x02013;0.81) and 0.6 (0.49&#x02013;0.74) for the controls respectively. The Kaplan-Meier analysis for all cases categorised by mean dose to LNL with RR (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) showed an inverse relationship between dose and survival. The OS rates were significantly higher for cases with a relapse in a LNL outside PTV (<italic>D</italic><sub>mean</sub> &#x0003c;40&#x000a0;Gy) (0.67 (0.42&#x02013;1.00)) than for those with a relapse in a LNL in the elective volume (<italic>D</italic><sub>mean</sub> 40&#x02013;60&#x000a0;Gy) (0.40 (0.14&#x02013;1.00) and in PTV<sub>tumour</sub> (<italic>D</italic><sub>mean</sub> &#x0003e;60&#x000a0;Gy) (0.11 (0.02&#x02013;0.71). A similar relative inverse relationship was shown for the more limited number of cases with known HPV-status (by p16 over expression in &#x0003e;70&#x000a0;% of the cells) divided in two groups according to <italic>D</italic><sub>mean</sub>. OS rate at five years was 0.5 (0.25&#x02013;1.00) for <italic>D</italic><sub>mean</sub> &#x0003c;60&#x000a0;Gy and none were alive at 5&#x000a0;years for <italic>D</italic><sub>mean</sub> &#x0003e;60&#x000a0;Gy (<italic>p</italic>&#x02009;=&#x02009;0.046).<fig id="Fig1"><label>Fig. 1</label><caption><p>Overall survival in cases and controls. Kaplan-Meier plot of overall survival in cases and controls (95&#x000a0;% CI)</p></caption><graphic xlink:href="13014_2015_422_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Overall survival in cases based on mean dose (<italic>D</italic>
<sub>mean</sub>). Kaplan-Meier plot of overall survival in cases divided according to mean dose to LNL of interest</p></caption><graphic xlink:href="13014_2015_422_Fig2_HTML" id="MO2"/></fig></p><p>Complementing the results presented in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, we performed a Cox regression with OS as dependent variable, adjusting for fractionation schedule (AFx vs. CFx) and neck surgery. The variables representing time to relapse and neck surgery were analyzed as a time-dependent (i.e. time at risk is counted from the day of the event until either end of follow up or death). The results are presented in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. No tested two-way interactions were statistically significant. When comparing cases and controls and not taking date of recurrence into account (i.e. not analyzing recurrence as a time-dependent variable) the hazard ratio for cases vs. controls was 2.74 (95&#x000a0;% CI 1.44&#x02013;5.21). A Cox regression analysis was also performed for cases only, with outcome OS complementing Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, comparing dose categories (&#x02264;40&#x000a0;Gy, 40&#x02009;&#x02264;&#x02009;60&#x000a0;Gy, &#x0003e;60&#x000a0;Gy) adjusted for fractionation schedule and neck surgery (analyzed as a time-dependent variable), Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>. No tested two-way interactions were statistically significant.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Overall survival in cases and controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>HR</th><th>CI</th><th>
<italic>p</italic>-value</th></tr></thead><tbody><tr><td>Regional relapse</td><td>3.56</td><td>1.84&#x02013;6.92</td><td>&#x0003c;0.001</td></tr><tr><td>Fx-schedule</td><td>0.88</td><td>0.49&#x02013;1.59</td><td>0.673</td></tr><tr><td>Neck dissection</td><td>0.85</td><td>0.45&#x02013;1.60</td><td>0.619</td></tr></tbody></table><table-wrap-foot><p>Cox regression analysis of overall survival in cases vs. controls adjusted for fractionation schedule and neck dissection</p></table-wrap-foot></table-wrap><table-wrap id="Tab5"><label>Table 5</label><caption><p>Overall survival in cases based on mean dose (<italic>D</italic>
<sub>mean</sub>)</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>HR</th><th>CI</th><th>
<italic>p</italic>-value</th></tr></thead><tbody><tr><td>40&#x02013;60</td><td>1.67</td><td>0.35&#x02013;7.98</td><td>0.522</td></tr><tr><td>60&#x02013;80</td><td>7.94</td><td>1.80&#x02013;35.04</td><td>0.006</td></tr><tr><td>Fx-schedule</td><td>1.96</td><td>0.54&#x02013;7.17</td><td>0.310</td></tr><tr><td>Neck dissection</td><td>1.83</td><td>0.59&#x02013;5.67</td><td>0.298</td></tr></tbody></table><table-wrap-foot><p>Cox regression analysis of overall survival in cases categorised according to dose interval in Gy adjusted for fractionation schedule and neck dissection. Dose &#x0003c;40 Gy is the reference category</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p>Our material indicates a risk reduction for regional recurrences (OR&#x02009;&#x0003c;&#x02009;0.2) in the dose interval corresponding to elective treatment (40&#x02013;50&#x000a0;Gy) with statistical significance in the logistic regression model for <italic>D</italic><sub>50%</sub> and a trend for <italic>D</italic><sub>mean</sub>. No significant risk reduction for regional relapse was found in our study for <italic>D</italic><sub>mean</sub> and <italic>D</italic><sub>50%</sub> in the other investigated dose intervals. One explanation for the lack of risk reduction for development of RR in <italic>D</italic><sub>50%</sub> and <italic>D</italic><sub>mean</sub> &#x0003e;50&#x000a0;Gy could be the close proximity to macroscopic tumour in these LNLs and thereby an inherent higher risk of relapse where a dose &#x0003c;60&#x000a0;Gy might not be sufficient. However, the number of cases and controls in this dose interval is small. A similar dose as suggested in our material has been proposed for elective treatment to the neck in recent studies where an equivalent dose in 2&#x000a0;Gy fractions, assuming &#x003b1;/&#x003b2;&#x02009;=&#x02009;10&#x000a0;Gy (EQD2<sub>10</sub>)&#x02009;&#x0003e;&#x02009;50&#x000a0;Gy, does not seem to improve regional control [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], whereas a dose&#x02009;&#x0003c;&#x02009;30&#x000a0;Gy in 2&#x000a0;Gy fractions has been shown to have a higher regional relapse rate [<xref ref-type="bibr" rid="CR32">32</xref>]. A prospective randomised trial investigating an EQD2<sub>10</sub> of 40&#x000a0;Gy to PTV<sub>elective</sub> presented encouraging toxicity outcome regarding dysphagia, but not yet tumour control data [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p>As the cohort for the present study consisted of patients with complete response after primary treatment, the OS of the cohort was somewhat better than the survival of all OPS presented in [<xref ref-type="bibr" rid="CR20">20</xref>]. In our study a regional relapse resulted in significantly reduced OS, both at five and twelve years. However, when deciding which LNLs to include in an elective target volume, the consequence on OS of a nodal recurrence outside of the target volume is highly relevant. The effect on OS of regional relapses categorised by delivered dose, however, is sparsely addressed in the literature. This prompted us to do a survival analysis for the cases grouped according to <italic>D</italic><sub>mean</sub> representing a relapse outside of the PTV (&#x0003c;40&#x000a0;Gy), in the PTV<sub>elective</sub> (40&#x02013;60&#x000a0;Gy), or in the PTV<sub>tumour</sub> (&#x0003e;60&#x000a0;Gy). A recurrence in PTV<sub>tumour</sub> has a major impact on OS, whereas a patient with a nodal relapse outside the PTVs has a survival comparable to that of the cohort. Our hypothesis, to this perhaps somewhat contra intuitive finding, is that the relapses in such heavily treated areas are selected to be more treatment resistant than a recurrence in a treatment naive LNL, as well as having more limited treatment options.</p><p>The finding that recurrences &#x0201c;out of field&#x0201d; have a survival comparable to the cohort could be an argument for future studies investigating limited elective target volumes omitting treatment to LNL with low risk of relapse in order to avoid late side effects of the treatment.</p><p>Since HPV is one of the most important prognostic factors in OPC treated with RT [<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>], we evaluated the OS in the cases with HPV-positive tumours divided according to <italic>D</italic><sub>mean</sub> to examine if the inverse relationship between dose and survival seen in all cases holds true for the HPV-positive cases as well. Because of the small number of cases with known HPV-status we restricted the analysis to <italic>D</italic><sub>mean</sub> &#x02264;60&#x000a0;Gy or <italic>D</italic><sub>mean</sub> &#x0003e;60&#x000a0;Gy in this group. In spite of the small number of cases there was still a significant difference in OS in patients with HPV-positive OPC divided according to dose similar to that shown for all cases. Recently a review of risk factors for loco-regional failure in HPV-associated OPC found that the only factors significant for risk stratification in multivariate analysis apart from smoking were T4- and N3-stages [<xref ref-type="bibr" rid="CR38">38</xref>], which were evenly distributed in our study between cases and controls. Only five of the HPV-positive cases had available smoking status (all non-smokers). Three of those had <italic>D</italic><sub>mean</sub> &#x02264;60&#x000a0;Gy and two had <italic>D</italic><sub>mean</sub> &#x0003e;60.</p><p>Two different fractionation schedules were used for the PTV<sub>tumour</sub> in the present study. The ARTSCAN study showed no significant difference in treatment response of lymph node metastases or regional relapses between the fractionation schedules and the use of AFx in our study. Thus the study was well balanced between cases and controls. Therefore no significant difference in outcome depending on fractionation schedule was expected.</p><p>Today advanced head and neck cancer is commonly treated with chemo-RT which has shown a survival benefit compared to RT alone [<xref ref-type="bibr" rid="CR39">39</xref>]. The presented dose&#x02013;response relationships in this study are investigated for RT without chemotherapy. Since HPV-associated OPC has a favourable outcome, voices are being raised for a possible de-escalation of the treatment to this entity of HNSCC [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. The incidence of HPV-associated OPC is steadily increasing and now constitutes up to 85&#x000a0;% of all OPC in Sweden [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Therefore we suggest that dose&#x02013;response relationships for RT without chemotherapy are clinically relevant.</p><p>According to the ARTSCAN-study protocol, the PTV<sub>elective</sub> was defined according to clinical practice at each participating centre. At the time of the study there was no clear consensus on what to treat electively in Sweden. This resulted in an up to two- fold variation in the size of the PTV<sub>elective</sub> with a substantial amount of unilateral and selective elective treatment in the study. Therefore the variation of dose delivered to the LNLs of the neck was only partly dependent on T- and N-stage. This allows analysis of dose&#x02013;response relationships of regional recurrences corrected for tumour stage. Moreover, the present study was performed on a patient material consisting solely of OPC, which reduces the possible bias of different risk of metastatic spread with respect to primary tumour site.</p></sec><sec id="Sec15" sec-type="conclusions"><title>Conclusions</title><p>Our study shows a significant risk reduction for the development of regional recurrences of elective treatment in the dose levels used in the present study compared to no prescribed elective treatment in OPC. However, in 319 patients treated with RT without chemotherapy, only 23 nodal recurrences occurred during five years of follow-up. Moreover the OS for patients with regional recurrence outside target volumes was not affected, with a similar pattern for a small subset of patients with known HPV-status. This could be an argument for a prospective randomised study on limited elective target volumes to reduce late side effects in OPC.</p></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>BZ and KS were involved in the study design (BZ, EK and PN for the initial ARTSCAN trial design); PN and KS was responsible for deriving the dose volume parameters; TD was responsible for the analysis of p16, KS was responsible for writing the manuscript; and PN, EK, TD and BZ were responsible for critical revision of the manuscript. All authors read and approved the final version of the manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by grants from the Swedish Cancer Society and the Cancer Research Foundation of Northern Sweden, the Stockholm Cancer Society and Cancer and Allergy Foundation. The study sponsors had no role in the study design, data collection, data analysis, writing, or submission of the manuscript. This study was made possible by the commitment from the staff at participating centres in the ARTSCAN study: Ume&#x000e5; University Hospital; Lund University Hospital; Malm&#x000f6; University Hospital; Karolinska University Hospital, Stockholm; &#x000d6;rebro University Hospital; Karlstad Central Hospital; Sahlgrenska University Hospital, G&#x000f6;teborg; Link&#x000f6;ping University Hospital; G&#x000e4;vle Hospital; Ryhov County Hospital, J&#x000f6;nk&#x000f6;ping; and Uppsala University Hospital.</p><p>The authors acknowledge Ove Bj&#x000f6;r, Regional Cancer Centre, Ume&#x000e5;, for statistical advice and analysis.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>GH</given-names></name><name><surname>Lindberg</surname><given-names>RD</given-names></name></person-group><article-title>Squamous cell carcinomas of the tonsillar area and palatine arch</article-title><source>Am J Roentgenol Radium Ther Nucl Med</source><year>1966</year><volume>96</volume><fpage>574</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.2214/ajr.96.3.574</pub-id><pub-id pub-id-type="pmid">5904868</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>GH</given-names></name></person-group><article-title>Elective irradiation of subclinical disease in cancers of the head and neck</article-title><source>Cancer</source><year>1972</year><volume>29</volume><fpage>1450</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(197206)29:6&#x0003c;1450::AID-CNCR2820290605&#x0003e;3.0.CO;2-Q</pub-id><pub-id pub-id-type="pmid">5031239</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabuzzi</surname><given-names>DD</given-names></name><name><surname>Chung</surname><given-names>CT</given-names></name><name><surname>Sagerman</surname><given-names>RH</given-names></name></person-group><article-title>Prophylactic neck irradiation</article-title><source>Arch Otolaryngol (Chicago, Ill : 1960)</source><year>1980</year><volume>106</volume><fpage>454</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1001/archotol.1980.00790320006002</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendenhall</surname><given-names>WM</given-names></name><name><surname>Million</surname><given-names>RR</given-names></name><name><surname>Cassisi</surname><given-names>NJ</given-names></name></person-group><article-title>Elective neck irradiation in squamous-cell carcinoma of the head and neck</article-title><source>Head Neck Surg</source><year>1980</year><volume>3</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1002/hed.2890030105</pub-id><pub-id pub-id-type="pmid">7410098</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendenhall</surname><given-names>WM</given-names></name><name><surname>Parsons</surname><given-names>JT</given-names></name><name><surname>Million</surname><given-names>RR</given-names></name></person-group><article-title>Elective lower neck irradiation: 5000 cGy/25 fractions versus 4050 cGy/15 fractions</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1988</year><volume>15</volume><fpage>439</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/S0360-3016(98)90027-X</pub-id><pub-id pub-id-type="pmid">3403324</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>August</surname><given-names>M</given-names></name><name><surname>Gianetti</surname><given-names>K</given-names></name></person-group><article-title>Elective neck irradiation versus observation of the clinically negative neck of patients with oral cancer</article-title><source>J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg</source><year>1996</year><volume>54</volume><fpage>1050</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/S0278-2391(96)90157-3</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boysen</surname><given-names>M</given-names></name><name><surname>Lovdal</surname><given-names>O</given-names></name><name><surname>Soberg</surname><given-names>R</given-names></name><name><surname>Jacobsen</surname><given-names>AB</given-names></name><name><surname>Tausjo</surname><given-names>J</given-names></name><name><surname>Evensen</surname><given-names>JF</given-names></name></person-group><article-title>Elective radiotherapy of the neck in patients with squamous cell carcinoma of the head and neck</article-title><source>ORL; J Oto-Rhino-Laryngol and its Related Specialties</source><year>1992</year><volume>54</volume><fpage>103</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1159/000276274</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christianen</surname><given-names>ME</given-names></name><name><surname>Schilstra</surname><given-names>C</given-names></name><name><surname>Beetz</surname><given-names>I</given-names></name><name><surname>Muijs</surname><given-names>CT</given-names></name><name><surname>Chouvalova</surname><given-names>O</given-names></name><name><surname>Burlage</surname><given-names>FR</given-names></name><etal/></person-group><article-title>Predictive modelling for swallowing dysfunction after primary (chemo) radiation: results of a prospective observational study</article-title><source>Radiother Oncol J Eur Soc Ther Radiol Oncol</source><year>2012</year><volume>105</volume><fpage>107</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2011.08.009</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisbruch</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name><name><surname>Feng</surname><given-names>FY</given-names></name><name><surname>Lyden</surname><given-names>TH</given-names></name><name><surname>Haxer</surname><given-names>MJ</given-names></name><name><surname>Feng</surname><given-names>M</given-names></name><etal/></person-group><article-title>Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2011</year><volume>81</volume><fpage>e93</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2010.12.067</pub-id><pub-id pub-id-type="pmid">21592678</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortensen</surname><given-names>HR</given-names></name><name><surname>Jensen</surname><given-names>K</given-names></name><name><surname>Aksglaede</surname><given-names>K</given-names></name><name><surname>Behrens</surname><given-names>M</given-names></name><name><surname>Grau</surname><given-names>C</given-names></name></person-group><article-title>Late dysphagia after IMRT for head and neck cancer and correlation with dose-volume parameters</article-title><source>Radiother Oncol J Eur Soc Ther Radiol Oncol</source><year>2013</year><volume>107</volume><fpage>288</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2013.06.001</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dirix</surname><given-names>P</given-names></name><name><surname>Nuyts</surname><given-names>S</given-names></name></person-group><article-title>Evidence-based organ-sparing radiotherapy in head and neck cancer</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(09)70231-1</pub-id><pub-id pub-id-type="pmid">20129131</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doornaert</surname><given-names>P</given-names></name><name><surname>Verbakel</surname><given-names>WF</given-names></name><name><surname>Rietveld</surname><given-names>DH</given-names></name><name><surname>Slotman</surname><given-names>BJ</given-names></name><name><surname>Senan</surname><given-names>S</given-names></name></person-group><article-title>Sparing the contralateral submandibular gland without compromising PTV coverage by using volumetric modulated arc therapy</article-title><source>Radiat Oncol (London, England)</source><year>2011</year><volume>6</volume><fpage>74</fpage><pub-id pub-id-type="doi">10.1186/1748-717X-6-74</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisbruch</surname><given-names>A</given-names></name><name><surname>Levendag</surname><given-names>PC</given-names></name><name><surname>Feng</surname><given-names>FY</given-names></name><name><surname>Teguh</surname><given-names>D</given-names></name><name><surname>Lyden</surname><given-names>T</given-names></name><name><surname>Schmitz</surname><given-names>PI</given-names></name><etal/></person-group><article-title>Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2007</year><volume>69</volume><fpage>S40</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.04.083</pub-id><pub-id pub-id-type="pmid">17848291</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisbruch</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Rasch</surname><given-names>C</given-names></name><name><surname>Vineberg</surname><given-names>K</given-names></name><name><surname>Damen</surname><given-names>E</given-names></name><name><surname>Van As</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT?</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2004</year><volume>60</volume><fpage>1425</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2004.05.050</pub-id><pub-id pub-id-type="pmid">15590174</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marur</surname><given-names>S</given-names></name><name><surname>D&#x02019;Souza</surname><given-names>G</given-names></name><name><surname>Westra</surname><given-names>WH</given-names></name><name><surname>Forastiere</surname><given-names>AA</given-names></name></person-group><article-title>HPV-associated head and neck cancer: a virus-related cancer epidemic</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><fpage>781</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(10)70017-6</pub-id><pub-id pub-id-type="pmid">20451455</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasman</surname><given-names>A</given-names></name><name><surname>Attner</surname><given-names>P</given-names></name><name><surname>Hammarstedt</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Eriksson</surname><given-names>M</given-names></name><name><surname>Giraud</surname><given-names>G</given-names></name><etal/></person-group><article-title>Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?</article-title><source>Int J Canc J Int Canc</source><year>2009</year><volume>125</volume><fpage>362</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1002/ijc.24339</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attner</surname><given-names>P</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Nasman</surname><given-names>A</given-names></name><name><surname>Hammarstedt</surname><given-names>L</given-names></name><name><surname>Ramqvist</surname><given-names>T</given-names></name><name><surname>Lindholm</surname><given-names>J</given-names></name><etal/></person-group><article-title>The role of human papillomavirus in the increased incidence of base of tongue cancer</article-title><source>Int J Canc J Int Canc</source><year>2010</year><volume>126</volume><fpage>2879</fpage><lpage>84</lpage></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramqvist</surname><given-names>T</given-names></name><name><surname>Dalianis</surname><given-names>T</given-names></name></person-group><article-title>An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention</article-title><source>Anticancer Res</source><year>2011</year><volume>31</volume><fpage>1515</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21617204</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaturvedi</surname><given-names>AK</given-names></name><name><surname>Anderson</surname><given-names>WF</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Curado</surname><given-names>MP</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers</article-title><source>J Clin Oncol Off J Am Soc Clin Oncol</source><year>2013</year><volume>31</volume><fpage>4550</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.50.3870</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zackrisson</surname><given-names>B</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Kjellen</surname><given-names>E</given-names></name><name><surname>Johansson</surname><given-names>KA</given-names></name><name><surname>Modig</surname><given-names>H</given-names></name><name><surname>Brun</surname><given-names>E</given-names></name><etal/></person-group><article-title>Two-year results from a Swedish study on conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma&#x02013;the ARTSCAN study</article-title><source>Radiother Oncol J Eur Soc Ther Radiol Oncol</source><year>2011</year><volume>100</volume><fpage>41</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2010.12.010</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>KA</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Zackrisson</surname><given-names>B</given-names></name><name><surname>Ohlson</surname><given-names>B</given-names></name><name><surname>Kjellen</surname><given-names>E</given-names></name><name><surname>Mercke</surname><given-names>C</given-names></name><etal/></person-group><article-title>The quality assurance process for the ARTSCAN head and neck study - a practical interactive approach for QA in 3DCRT and IMRT</article-title><source>Radiother Oncol J Eur SocTher Radiol Oncol</source><year>2008</year><volume>87</volume><fpage>290</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2007.12.005</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">International Commision of Radiation Units and Measurements, ICRU report 50: Prescribing, recording, and reporting photon-beam therapy. Bethesda; 1993. ICRU;1993 (ISBN 0-913394-48-3).</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">International Commision of Radiation Units and Measurements, ICRU report 62: Prescribing, recording, and reporting photon-beam therapy (supplement to ICRU report 50). Bethesda; 1999. ICRU;1999 (ISBN 0-913394-61-0).</mixed-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>KT</given-names></name><name><surname>Medina</surname><given-names>JE</given-names></name><name><surname>Wolfe</surname><given-names>GT</given-names></name><name><surname>Levine</surname><given-names>PA</given-names></name><name><surname>Sessions</surname><given-names>RB</given-names></name><name><surname>Pruet</surname><given-names>CW</given-names></name></person-group><article-title>Standardizing neck dissection terminology. Official report of the Academy&#x02019;s Committee for Head and Neck Surgery and Oncology</article-title><source>Arch Otolaryngol Head Neck Surg</source><year>1991</year><volume>117</volume><fpage>601</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1001/archotol.1991.01870180037007</pub-id><pub-id pub-id-type="pmid">2036180</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregoire</surname><given-names>V</given-names></name><name><surname>Coche</surname><given-names>E</given-names></name><name><surname>Cosnard</surname><given-names>G</given-names></name><name><surname>Hamoir</surname><given-names>M</given-names></name><name><surname>Reychler</surname><given-names>H</given-names></name></person-group><article-title>Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience</article-title><source>Radiother Oncol J Eur SocTher Radiol Oncol</source><year>2000</year><volume>56</volume><fpage>135</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/S0167-8140(00)00202-4</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregoire</surname><given-names>V</given-names></name><name><surname>Eisbruch</surname><given-names>A</given-names></name><name><surname>Hamoir</surname><given-names>M</given-names></name><name><surname>Levendag</surname><given-names>P</given-names></name></person-group><article-title>Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck</article-title><source>Radiother Oncol J Eur SocTher Radiol Oncol</source><year>2006</year><volume>79</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2006.03.009</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregoire</surname><given-names>V</given-names></name><name><surname>Levendag</surname><given-names>P</given-names></name><name><surname>Ang</surname><given-names>KK</given-names></name><name><surname>Bernier</surname><given-names>J</given-names></name><name><surname>Braaksma</surname><given-names>M</given-names></name><name><surname>Budach</surname><given-names>V</given-names></name><etal/></person-group><article-title>CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines</article-title><source>Radiother Oncol J Eur SocTher Radiol Oncol</source><year>2003</year><volume>69</volume><fpage>227</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2003.09.011</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ang</surname><given-names>KK</given-names></name><name><surname>Harris</surname><given-names>J</given-names></name><name><surname>Wheeler</surname><given-names>R</given-names></name><name><surname>Weber</surname><given-names>R</given-names></name><name><surname>Rosenthal</surname><given-names>DI</given-names></name><name><surname>Nguyen-Tan</surname><given-names>PF</given-names></name><etal/></person-group><article-title>Human papillomavirus and survival of patients with oropharyngeal cancer</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0912217</pub-id><pub-id pub-id-type="pmid">20530316</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begum</surname><given-names>S</given-names></name><name><surname>Gillison</surname><given-names>ML</given-names></name><name><surname>Ansari-Lari</surname><given-names>MA</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Westra</surname><given-names>WH</given-names></name></person-group><article-title>Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin</article-title><source>Clin Canc Res Off J Am Assoc Canc Res</source><year>2003</year><volume>9</volume><fpage>6469</fpage><lpage>75</lpage></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duprez</surname><given-names>F</given-names></name><name><surname>Bonte</surname><given-names>K</given-names></name><name><surname>De Neve</surname><given-names>W</given-names></name><name><surname>Boterberg</surname><given-names>T</given-names></name><name><surname>De Gersem</surname><given-names>W</given-names></name><name><surname>Madani</surname><given-names>I</given-names></name></person-group><article-title>Regional relapse after intensity-modulated radiotherapy for head-and-neck cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2011</year><volume>79</volume><fpage>450</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.10.028</pub-id><pub-id pub-id-type="pmid">20381266</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dandekar</surname><given-names>V</given-names></name><name><surname>Morgan</surname><given-names>T</given-names></name><name><surname>Turian</surname><given-names>J</given-names></name><name><surname>Fidler</surname><given-names>MJ</given-names></name><name><surname>Showel</surname><given-names>J</given-names></name><name><surname>Nielsen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Patterns-of-failure after helical tomotherapy-based chemoradiotherapy for head and neck cancer: implications for CTV margin, elective nodal dose and bilateral parotid sparing</article-title><source>Oral Oncol</source><year>2014</year><volume>50</volume><fpage>520</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2014.02.009</pub-id><pub-id pub-id-type="pmid">24613544</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suwinski</surname><given-names>R</given-names></name><name><surname>Maciejewski</surname><given-names>B</given-names></name><name><surname>Withers</surname><given-names>HR</given-names></name></person-group><article-title>Dose&#x02013;response relationship for elective neck irradiation of head and neck cancer&#x02013;facts and controversies</article-title><source>Neoplasma</source><year>1998</year><volume>45</volume><fpage>107</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">9687892</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuyts</surname><given-names>S</given-names></name><name><surname>Lambrecht</surname><given-names>M</given-names></name><name><surname>Duprez</surname><given-names>F</given-names></name><name><surname>Daisne</surname><given-names>JF</given-names></name><name><surname>Van Gestel</surname><given-names>D</given-names></name><name><surname>Van den Weyngaert</surname><given-names>D</given-names></name><etal/></person-group><article-title>Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity</article-title><source>Radiother Oncol J Eur SocTher Radiol Oncol</source><year>2013</year><volume>109</volume><fpage>323</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2013.06.044</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>P</given-names></name><name><surname>Eriksen</surname><given-names>JG</given-names></name><name><surname>Krogdahl</surname><given-names>A</given-names></name><name><surname>Therkildsen</surname><given-names>MH</given-names></name><name><surname>Ulhoi</surname><given-names>BP</given-names></name><name><surname>Overgaard</surname><given-names>M</given-names></name><etal/></person-group><article-title>The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&#x00026;7 trial</article-title><source>Radiother Oncol J Eur SocTher Radiol Oncol</source><year>2011</year><volume>100</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2011.02.010</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>P</given-names></name></person-group><article-title>The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome</article-title><source>Radiother Oncol J Eur SocTher Radiol Oncol</source><year>2010</year><volume>95</volume><fpage>371</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2010.04.022</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rischin</surname><given-names>D</given-names></name><name><surname>Young</surname><given-names>RJ</given-names></name><name><surname>Fisher</surname><given-names>R</given-names></name><name><surname>Fox</surname><given-names>SB</given-names></name><name><surname>Le</surname><given-names>QT</given-names></name><name><surname>Peters</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial</article-title><source>J Clin Oncol Off J Am Soc Clin Oncol</source><year>2010</year><volume>28</volume><fpage>4142</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.29.2904</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ang</surname><given-names>KK</given-names></name><name><surname>Sturgis</surname><given-names>EM</given-names></name></person-group><article-title>Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma</article-title><source>Semin Radiat Oncol</source><year>2012</year><volume>22</volume><fpage>128</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.semradonc.2011.12.004</pub-id><pub-id pub-id-type="pmid">22385920</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vainshtein</surname><given-names>JM</given-names></name><name><surname>Spector</surname><given-names>ME</given-names></name><name><surname>McHugh</surname><given-names>JB</given-names></name><name><surname>Wong</surname><given-names>KK</given-names></name><name><surname>Walline</surname><given-names>HM</given-names></name><name><surname>Byrd</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer</article-title><source>Oral Oncol</source><year>2014</year><volume>50</volume><fpage>513</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2014.02.001</pub-id><pub-id pub-id-type="pmid">24565983</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanchard</surname><given-names>P</given-names></name><name><surname>Baujat</surname><given-names>B</given-names></name><name><surname>Holostenco</surname><given-names>V</given-names></name><name><surname>Bourredjem</surname><given-names>A</given-names></name><name><surname>Baey</surname><given-names>C</given-names></name><name><surname>Bourhis</surname><given-names>J</given-names></name><etal/></person-group><article-title>Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site</article-title><source>Radiother Oncol J Eur SocTher Radiol Oncol</source><year>2011</year><volume>100</volume><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2011.05.036</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sturgis</surname><given-names>EM</given-names></name><name><surname>Ang</surname><given-names>KK</given-names></name></person-group><article-title>The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms?</article-title><source>J Natl Compr Canc Netw</source><year>2011</year><volume>9</volume><fpage>665</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">21636538</pub-id></element-citation></ref></ref-list></back></article>